The TRACK-TBI* Network, in conjunction with researchers at Abbott, recently announced FDA clearance for the first commercially available blood test to help evaluate mild traumatic brain injury (mTBI) or concussion. The TRACK-TBI Network is a collaboration among top tier TBI clinical research sites across the United States seeking to improve precision and efficiency in diagnosing TBI and evaluating treatments to improve outcomes for TBI patients.
Through involvement in the TRACK-TBI Network, our site (including Dr. Richard Rodgers, Nicole Lemrick, RN, AJ Mandery, NP, and the Goodman Campbell Brain and Spine research team at Ascension St. Vincent) was invited to participate in the trial helping to validate this new diagnostic tool. The study, sponsored by Abbott Point of Care, Inc, is coordinated through the University of California, San Francisco and supported by a public-private partnership that includes the United States Department of Defense. Our site was one of 20 across the US.
The TBI blood test can be utilized in healthcare settings and has the potential for expanded use outside of the hospital. It provides a triage tool for consideration in the determination of a need for further TBI evaluation, including CT scan. View the full article here.
GCBS is excited to play a role in the clinical evaluation of this technology, furthering our mission of innovation and advancement of healthcare. “As we recognize TBI awareness month, Goodman Campbell continues to strive to improve outcomes for our patients through preeminent clinical care and clinical research,” stated Heather Cero, Goodman Campbell Brain and Spine Director of Research.
Visit Research and Clinical Trials to learn more about some of our current studies and publications.
*Transforming Research and Clinical Knowledge in Traumatic Brain Injury